Northrop Grumman (NYSE: NOC) has said its fourth-quarter earnings declined despite a double-digit increase in sales. The aerospace company also provided guidance for fiscal 2023.
December-quarter sales moved up 16% year-over-year to $10.03 billion, reflecting broad-based growth across all operating segments. The management expects an increase in sales for fiscal 2023.
| OUTLOOK | FY2022 | FY2023 |
| sales | $36.6billion | $38billion — $38.4billion |
| MTM-adjusted EPS | $25.54 | $21.85 —$ 22.45 |
| Capital expenditures | $1.44billion | $1.65billion — $1.7billion |
| Adjusted Free cash flow | $1.62billion | $1.85billion — $2.15billion |
Despite the impressive sales performance, fourth-quarter net profit declined to $2.08 billion or $13.46 per share from $2.71 billion or $17.14 per share in the corresponding period of the prior year. Meanwhile, MTM-adjusted earnings increased to $7.50 per share from $6.00 per share last year.
“Given our proven ability to competitively win, hire and perform, we’re raising our sales outlook for 2023 and expect to deliver strong multi-year cash flow growth. We are focused on executing our strategy, investing in the capabilities and capacity our customers need, and returning a significant portion of our growing cash flows to our shareholders,” said the company’s CEO Kathy Warden.
Looking for more insights on the earnings results? Click here to access the full transcripts of the latest earnings conference calls!
Most Popular
Key takeaways from JM Smucker’s (SJM) Q4 2025 earnings report
Shares of The J.M. Smucker Co. (NYSE: SJM) plunged 15% on Tuesday after the company delivered mixed results for the fourth quarter of 2025. While earnings came ahead of expectations,
J.M. Smucker (SJM) Q4 2025 Earnings: Key financials and quarterly highlights
The J.M. Smucker Co. (NYSE: SJM) reported its fourth quarter 2025 earnings results today. Net sales was $2.1 billion, down 3% year-over-year. Comparable net sales decreased 1%. Net loss was
Plus Therapeutics CEO: Lead candidate REYOBIQ demonstrates strong safety and efficacy in early trials
Plus Therapeutics (NASDAQ: PSTV) is a pharmaceutical company engaged in the development of targeted radiotherapeutics for difficult-to-treat cancers. Currently, it is advancing a pipeline of product candidates with lead programs
